A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and
Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-
3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
(KEYNOTE-867
